angiotensin converting enzyme (ACE) inhibitors, trandolapril (4 mg/d), added to standard treatment
DISEASE INTERVENTION COMPARISON RESULTS
N Engl J Med. 2004 Nov 11;351(20):2058-68 Randomized Controlled Trial, Multicenter Study
IN coronary disease, stable, normal left ventricular function, most patients previous revascularization The Use of
angiotensin converting enzyme (ACE) inhibitors, trandolapril (4 mg/d), added to standard treatment
As Treatment, Chronic
Is equal Than
placebo
To reduce cardiac events (death from cardiovascular causes, myocardial infarction, or coronary revascularization): 21.9% in trandolapil VS 22.5% in placebo - at 5 years (so, aprox. 4.4% per year event rate)